

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	10/809,089	Art Unit:	4173
Applicant(s):	Andrew R. MARKS et al.	Examiner:	Benjamin J. Packard
Date Filed:	March 25, 2004	Conf. No.	7653
Docket No.	19240.596-US1	Cust. No.	56949
Title:	NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF		

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111

In response to the Office Action dated November 27, 2007, Applicants submit the enclosed Amendment and Reply under 37 C.F.R. § 1.111 for entry in the above-identified application. Enclosed herewith are a Supplemental Information Disclosure Statement, a Form SB/08 disclosing the references, a copy of the references, four (4) new drawing sheets which contain Figures 15-18, and an Appendix B. Also enclosed is a petition for extension of time for three (3) months with the required fee, accordingly this response is being timely filed.

Amendments to the Specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims which begins on page 5.

Remarks begin on page 11.